Primary Immunodeficiency Disorders Global Market Report 2025

Description

Primary immunodeficiency disorders (PIDs) are inherited conditions that impair the immune system, making individuals more susceptible to infections, autoimmune diseases, and certain cancers. Early diagnosis and identification of PIDs are critical for effective treatment, infection prevention, and improving patient health through therapies such as immunoglobulin replacement or bone marrow transplants.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of primary immunodeficiency disorders include antibody deficiencies, cellular immunodeficiencies, innate immune disorders, and others. Antibody deficiencies occur when the immune system is unable to produce sufficient antibodies, which are responsible for detecting and neutralizing harmful pathogens. Treatments available include immunoglobulin replacement therapy, antibiotic treatment, stem cell or bone marrow transplants, gene therapy, and other methods. Diagnostic approaches involve genetic testing, blood tests, flow cytometry, and other techniques, which are typically applied in hospitals, specialty clinics, home care settings, and research institutions.

The primary immunodeficiency disorders market research report is one of a series of new reports from The Business Research Company that provides primary immunodeficiency disorders market statistics, including the primary immunodeficiency disorders industry's global market size, regional shares, competitors with a primary immunodeficiency disorders market share, detailed primary immunodeficiency disorders market segments, market trends and opportunities, and any further data you may need to thrive in the primary immunodeficiency disorders industry. This primary immunodeficiency disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The primary immunodeficiency disorders market size has grown strongly in recent years. It will grow from$6.84 billion in 2024 to $7.32 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be attributed to the rising incidence of primary immunodeficiency disorders, increased awareness among healthcare professionals, growing demand for effective treatments, higher research funding, and an increased focus on pediatric care.

The primary immunodeficiency disorders market size is expected to see strong growth in the next few years. It will grow to$9.51 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to the growing adoption of subcutaneous therapies, improved healthcare access, robust research and development, a higher demand for efficient treatments, and an increasing need for immunoglobulin replacement therapy. Major trends in the forecast period include advancements in biotechnology, innovative gene therapies and biologics, progress in genetic testing and personalized medicine, and ongoing advancements in gene therapy and genetic tests.

The increasing prevalence of autoimmune diseases is anticipated to drive the growth of the primary immunodeficiency disorders market. Autoimmune diseases occur when the immune system erroneously attacks the body's healthy cells and tissues, perceiving them as foreign invaders. This misdirected immune response leads to inflammation and damage across various organs and systems. The rise in autoimmune diseases is attributed to a complex mix of environmental factors, genetic predispositions, and lifestyle changes. These diseases can cause primary immunodeficiency disorders by disrupting immune regulation and attacking immune cells, resulting in weakened or impaired immune responses. For example, in November 2024, data from Versorgungsatlas.de, an interactive online platform in Germany, revealed that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. This increasing prevalence of autoimmune diseases is a key driver behind the expansion of the primary immunodeficiency disorders market.

Leading companies in the primary immunodeficiency disorders market are focusing on the development of advanced therapies such as intravenous immunoglobulin (IVIG) therapy to enhance patient outcomes by improving immune function. IVIG therapy involves administering immunoglobulins (antibodies) derived from donor plasma directly into a patient's bloodstream through an IV. For instance, in June 2024, Grifols, a healthcare company based in Spain, received FDA approval for Yimmugo, an intravenous immunoglobulin (IVIg) therapy. This new sugar-free, ready-to-use IgG solution, derived from human blood plasma, is intended for intravenous administration. It was approved in the U.S. for substitution therapy in patients with primary antibody deficiency syndromes. Yimmugo provides antibody replacement to support individuals with immune deficiencies, enhancing Grifols' portfolio of plasma-based treatments by offering a safer and more effective solution to protect against infections.

In April 2022, Grifols, S.A., a pharmaceutical company based in Spain, acquired Biotest AG for an undisclosed amount. This acquisition is aimed at accelerating growth and fostering innovation by expanding Grifols' plasma-derived medicines portfolio and strengthening its global market presence. Biotest AG, a biotechnology company based in Germany, specializes in plasma proteins and biological drugs.

Major players in the primary immunodeficiency disorders market are Pfizer Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceuticals, CSL Behring, Baxter International Inc., Grifols SA, Octapharma, Kedrion Biopharma, Miltenyi Biotec, LFB Group, Clinigen Limited, ADMA Biologics Inc., Bio Products Laboratory Ltd, BD Biosciences, Cellectis SA, Florencia Healthcare, X4 Pharmaceuticals Inc., Amber Lifesciences, bluebird bio Inc., and Chengdu Rongsheng Pharmaceutical Co Ltd.

North America was the largest region in the primary immunodeficiency disorders market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary immunodeficiency disorders report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the primary immunodeficiency disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary immunodeficiency disorders market consists of revenues earned by entities by providing services such as immunoglobulin therapy, rehabilitation and support programs, educational and advocacy services, and personalized treatment plans. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary immunodeficiency disorders market also includes sales of vaccines, antibiotics, antifungals, and small molecule drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Immunodeficiency Disorders Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on primary immunodeficiency disorders market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary immunodeficiency disorders ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary immunodeficiency disorders market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Disease: Antibody Deficiency; Cellular Immunodeficiency; Innate Immune Disorders; Other Diseases
2) By Treatment: Immunoglobulin Replacement Therapy; Antibiotic Therapy; Stem Cell And Bone Marrow Transplantation; Gene Therapy; Other Treatments
3) By Diagnostic Type: Genetic Testing; Blood Testing; Flow Cytometry; Other Diagnostic Types
4) By End-User: Hospitals; Specialty Clinics; Homecare Settings; Research Institutions
Subsegments:
1) By Antibody Deficiency: Common Variable Immune Deficiency (CVID); IgA Deficiency; IgG Subclass Deficiency; Specific Antibody Deficiency
2) By Cellular Immunodeficiency: Severe Combined Immunodeficiency (SCID); T-Cell Deficiency; DiGeorge Syndrome; Wiskott-Aldrich Syndrome
3) By Innate Immune Disorders: Chronic Granulomatous Disease (CGD); Complement Deficiencies; Toll-like Receptor Deficiencies; Chediak-Higashi Syndrome
4) By Other Diseases: Hyper IgM Syndrome; Hyper IgE Syndrome; Ataxia-Telangiectasia; Combined Immunodeficiencies With Syndromic Features
Companies Mentioned: Pfizer Inc.; Thermo Fisher Scientific Inc.; Takeda Pharmaceuticals; CSL Behring; Baxter International Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34935

1. Executive Summary

2. Primary Immunodeficiency Disorders Market Characteristics

3. Primary Immunodeficiency Disorders Market Trends And Strategies

4. Primary Immunodeficiency Disorders Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Primary Immunodeficiency Disorders Growth Analysis And Strategic Analysis Framework

5.1. Global Primary Immunodeficiency Disorders PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Primary Immunodeficiency Disorders Market Growth Rate Analysis
5.4. Global Primary Immunodeficiency Disorders Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Primary Immunodeficiency Disorders Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Primary Immunodeficiency Disorders Total Addressable Market (TAM)

6. Primary Immunodeficiency Disorders Market Segmentation

6.1. Global Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antibody Deficiency
Cellular Immunodeficiency
Innate Immune Disorders
Other Diseases
6.2. Global Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunoglobulin Replacement Therapy
Antibiotic Therapy
Stem Cell And Bone Marrow Transplantation
Gene Therapy
Other Treatments
6.3. Global Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Genetic Testing
Blood Testing
Flow Cytometry
Other Diagnostic Types
6.4. Global Primary Immunodeficiency Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Homecare Settings
Research Institutions
6.5. Global Primary Immunodeficiency Disorders Market, Sub-Segmentation Of Antibody Deficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Common Variable Immune Deficiency (CVID)
IgA Deficiency
IgG Subclass Deficiency
Specific Antibody Deficiency
6.6. Global Primary Immunodeficiency Disorders Market, Sub-Segmentation Of Cellular Immunodeficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Severe Combined Immunodeficiency (SCID)
T-Cell Deficiency
DiGeorge Syndrome
Wiskott-Aldrich Syndrome
6.7. Global Primary Immunodeficiency Disorders Market, Sub-Segmentation Of Innate Immune Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chronic Granulomatous Disease (CGD)
Complement Deficiencies
Toll-like Receptor Deficiencies
Chediak-Higashi Syndrome
6.8. Global Primary Immunodeficiency Disorders Market, Sub-Segmentation Of Other Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hyper IgM Syndrome
Hyper IgE Syndrome
Ataxia-Telangiectasia
Combined Immunodeficiencies With Syndromic Features

7. Primary Immunodeficiency Disorders Market Regional And Country Analysis

7.1. Global Primary Immunodeficiency Disorders Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Primary Immunodeficiency Disorders Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Primary Immunodeficiency Disorders Market

8.1. Asia-Pacific Primary Immunodeficiency Disorders Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Primary Immunodeficiency Disorders Market

9.1. China Primary Immunodeficiency Disorders Market Overview
9.2. China Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Primary Immunodeficiency Disorders Market

10.1. India Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Primary Immunodeficiency Disorders Market

11.1. Japan Primary Immunodeficiency Disorders Market Overview
11.2. Japan Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Primary Immunodeficiency Disorders Market

12.1. Australia Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Primary Immunodeficiency Disorders Market

13.1. Indonesia Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Primary Immunodeficiency Disorders Market

14.1. South Korea Primary Immunodeficiency Disorders Market Overview
14.2. South Korea Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Primary Immunodeficiency Disorders Market

15.1. Western Europe Primary Immunodeficiency Disorders Market Overview
15.2. Western Europe Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Primary Immunodeficiency Disorders Market

16.1. UK Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Primary Immunodeficiency Disorders Market

17.1. Germany Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Primary Immunodeficiency Disorders Market

18.1. France Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Primary Immunodeficiency Disorders Market

19.1. Italy Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Primary Immunodeficiency Disorders Market

20.1. Spain Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Primary Immunodeficiency Disorders Market

21.1. Eastern Europe Primary Immunodeficiency Disorders Market Overview
21.2. Eastern Europe Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Primary Immunodeficiency Disorders Market

22.1. Russia Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Primary Immunodeficiency Disorders Market

23.1. North America Primary Immunodeficiency Disorders Market Overview
23.2. North America Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Primary Immunodeficiency Disorders Market

24.1. USA Primary Immunodeficiency Disorders Market Overview
24.2. USA Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Primary Immunodeficiency Disorders Market

25.1. Canada Primary Immunodeficiency Disorders Market Overview
25.2. Canada Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Primary Immunodeficiency Disorders Market

26.1. South America Primary Immunodeficiency Disorders Market Overview
26.2. South America Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Primary Immunodeficiency Disorders Market

27.1. Brazil Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Primary Immunodeficiency Disorders Market

28.1. Middle East Primary Immunodeficiency Disorders Market Overview
28.2. Middle East Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Primary Immunodeficiency Disorders Market

29.1. Africa Primary Immunodeficiency Disorders Market Overview
29.2. Africa Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Primary Immunodeficiency Disorders Market Competitive Landscape And Company Profiles

30.1. Primary Immunodeficiency Disorders Market Competitive Landscape
30.2. Primary Immunodeficiency Disorders Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Takeda Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. CSL Behring Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Primary Immunodeficiency Disorders Market Other Major And Innovative Companies

31.1. Grifols SA
31.2. Octapharma
31.3. Kedrion Biopharma
31.4. Miltenyi Biotec
31.5. LFB Group
31.6. Clinigen Limited
31.7. ADMA Biologics Inc.
31.8. Bio Products Laboratory Ltd
31.9. BD Biosciences
31.10. Cellectis SA
31.11. Florencia Healthcare
31.12. X4 Pharmaceuticals Inc.
31.13. Amber Lifesciences
31.14. bluebird bio Inc.
31.15. Chengdu Rongsheng Pharmaceutical Co Ltd

32. Global Primary Immunodeficiency Disorders Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Primary Immunodeficiency Disorders Market

34. Recent Developments In The Primary Immunodeficiency Disorders Market

35. Primary Immunodeficiency Disorders Market High Potential Countries, Segments and Strategies

35.1 Primary Immunodeficiency Disorders Market In 2029 - Countries Offering Most New Opportunities
35.2 Primary Immunodeficiency Disorders Market In 2029 - Segments Offering Most New Opportunities
35.3 Primary Immunodeficiency Disorders Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer
250617_r34935_Primary_Immunodeficiency_Disorders_GMR_2025